Search for a trial

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Primary Objective: To assess the change from baseline in 24-hr albuminuria with dapagliflozin for six weeks relative to placebo treatment in patients with diabetes and albuminuria > 100 mg/day on stable ACEi or ARB treatment.Secondary…

RAAS-blockade in type II diabetes: added effects of a low sodium diet and diuretics.

Determinination of the added effects of dietary sodium restriction or diuretic use to antihypertensive and antialbuminuric therapy.

Mechanisms of Albuminuria in Diabetes: Reversal of Injury to the Glycocalyx by the Ace-inhibitor Lisinopril

The primary objective of this study is to determine whether ACE inhibition results in an improvement of microvascular glycocalyx-thickness in patients with type 1 diabetes. The secondary objectives are to investigate whether this (hypothesized)…

Individual albuminuria lowering response to dapagliflozin in a decentralized
clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria

Primary: To determine the individual response to the SGTL2 inhibitor dapagliflozin in urine albumin-to-creatinine ratio (UACR) Secondary:- To determine the individual response to the SGLT2 inhibitor dapagliflozin in: - Systolic blood pressure - Body…

A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with either preserved or impaired kidney function with or without type 2 diabetes

We aim to investigate the renal hemodynamic effects of empagliflozin in people with either preserved or impaired renal function with T2DM and people with impaired renal function without T2DM, all with and without adenosine blockade.

Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia

This study has been transitioned to CTIS with ID 2024-518855-43-00 check the CTIS register for the current data. Primary objective: To evaluate the effect of SGLT2 inhibition with dapagliflozin 10 mg on serum magnesium in diabetic and non-diabetic…

A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients elevated Albuminuria: a Randomized Double Blind Cross-Over Trial

This study investigates how well the combination of the two drugs, zibotentan and dapagliflozin, works for the treatment of chronic kidney disease in patients. We compare the effect of zibotentan and dapagliflozin with the effect of a placebo. The…

DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes

This study has been transitioned to CTIS with ID 2023-510257-42-01 check the CTIS register for the current data. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lead to a lowering of blood pressure and confer cardiovascular and renal protection in…

Wishing to decrease Aquaresis in ADPKD patients Treated with a V2Ra; the Effect of Regulating protein and salt

To demonstrate the effect of salt and/or protein intake on aquaresis in patients with ADPKD who are treated with a vasopressin V2 receptor antagonist as measured by 24-hour urine volume.

A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus

Investigate the effects of 7 (+-1) days of of mono- and combination therapy with the SGLT2 inhibitor empagliflozin (10 mg QD) and RAS inhibitor losartan (50 mg QD) on renal hemodynamics, (glomerular filtration rate (GFR) / effective renal plasma…

Exploratory study into the effect of salt supplementation in Gitelman syndrome

To determine the effect of salt (NaCl) supplementation on (1) physiological parameters (such as serum potassium) and on (2) clinical signs and symptoms and quality of life.

Potassium supplementation in patients with chronic kidney disease and healthy subjects: effects on potassium and sodium balance

To investigate how acute potassium administration affects potassium and sodium balance in healthy subjects as compared to patients at different CKD stages, i.e., normal kidney function and stage 3b/4 CKD.

Explorative study to investige the acid-base response to five sodium and potassium salts in patients with chronic kidney disease (5Z study)

Test the effect of five different sodium- and potassium salts in patients with chronic kidney disease.

Hydrochlorothiazide and metformin cross-over study for attenuating aquaretic side-effects in ADPKD patients treated with tolvaptan

To demonstrate whether hydrochlorothiazide or metformin can diminish aquaresis in patients with ADPKD who are treated with tolvaptan as measured by 24-hour urine volume.

Effect of amiloride on polyuria and well being in lithium treated patients

Primary objective: to investigate the effect of amiloride on urine volume and urinary concentrating ability in patients on chronic lithium therapy suffering from polyuria.We hypothesize that amiloride therapy will improve urinary concentating…